Page 964 - Read Online

Page 8 of 11 Brodosi et al. Hepatoma Res 2020;6:82 I http://dx.doi.org/10.20517/2394-5079.2020.88

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2020.

REFERENCES
1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-
analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84.
2. Petta S, Di Marco V, Pipitone RM, et al. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: genetic and
metabolic risk factors in a general population. Liver Int 2018;38:2060-8.
3. Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a
systematic review and meta-analysis. Gastroenterology 2020;158:1611-25.e12.
4. Loria P, Marchesini G, Nascimbeni F, et al. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic
and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014;232:99-109.
5. Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol 2006;54:229-39.
6. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, et al. Long-term follow-up of patients with NAFLD and elevated liver
enzymes. Hepatology 2006;44:865-73.
7. Italian Association for the Study of the Liver (AISF). AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and
future directions. Dig Liver Dis 2017;49:471-83.
8. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association
for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver
disease. J Hepatol 2016;64:1388-402.
9. Sanyal AJ. Past, present and future perspectives in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2019;16:377-86.
10. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011;54:344-53.
11. Rinella ME, Noureddin M. STELLAR 3 and STELLAR 4: lessons from the fall of Icarus. J Hepatol 2020;73:9-11.
12. Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a
multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2019;394:2184-96.
13. Intercept release. Complete Response Letter (CRL) from the FDA regarding our new drug application for obeticholic acid (OCA) for
the treatment of liver fibrosis due to NASH. Available from: https://ir.interceptpharma.com/news-releases/news-release-details/intercept-
receives-complete-response-letter-fda-obeticholic-acid;2020. [Last accessed on 22 Oct 2020]
14. Portillo-Sanchez P, Bril F, Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus
and normal plasma aminotransferase levels. J Clin Endocrinol Metab 2015;100:2231-8.
15. Hazlehurst JM, Woods C, Marjot T, Cobbold JF, Tomlinson JW. Non-alcoholic fatty liver disease and diabetes. Metabolism
2016;65:1096-108.
16. Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin
Gastroenterol Hepatol 2009;7:1224-9, 29.e1-2.
17. Jarvis H, Craig D, Barker R, et al. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD):
a systematic review and meta-analysis of population-based observational studies. PLoS Med 2020;17:e1003100.
18. Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2
diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol 2016;31:936-44.
19. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology
2003;37:917-23.
20. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
21. Taylor R. Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 2008;51:1781-9.
22. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020.
Diabetes Care 2020;43:S98-110.
23. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with
type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diab Endocrinol 2019;7:776-85.
24. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in
type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019;393:31-9.
25. U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research. Guidance for Industry. Diabetes
mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Available from: http://wwwfdagov/
downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627pdf. [Last accessed on 22 Oct 2020]
26. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med